• Login
    View Item 
    •   Home
    • 4 Research Resources
    • MSF Research Protocols
    • View Item
    •   Home
    • 4 Research Resources
    • MSF Research Protocols
    • View Item
    Jan 17, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Final_protocol_secondary_proph ...
    Size:
    568.1Kb
    Format:
    Microsoft Word 2007
    Description:
    Research Protocol
    DownloadPDF Variant
    Authors
    Diro, Ermias
    Griensven, Johan van
    Woldegebreal, Teklu
    Belew, Zewdu
    Taye, Melese
    Yifru, Sisay
    Davidson, Robert N.
    Balasegaram, Manica
    Lynen, Lut
    Boelaert, Marleen
    Affiliation
    MSF-OCA
    Issue Date
    2018-07
    
    Metadata
    Show full item record
    Abstract
    2.1 OBJECTIVES 2.1.1 General objective: To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients that have documented parasite clearance after VL treatment when used for prevention of VL relapse. 2.1.2 Specific objectives of the primary study period 2.1.2.1 Primary objectives In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the effectiveness of PSP in terms of preventing relapse and death; - to assess the safety of PSP in terms of drug-related serious adverse events or permanent drug discontinuations due to adverse events; - to assess the feasibility of PSP in terms of number of patients compliant to therapy during the first year of monthly PM secondary prophylaxis. 2.1.2.2 Secondary objectives; In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the safety of PSP in terms of: - drug-related non-serious adverse events - serious adverse events (drug-related or not) - to assess the feasibility of PSP in terms of: - number of treatment interruptions/discontinuations, - number of therapeutic interventions needed to treat adverse drug reactions
    URI
    http://hdl.handle.net/10144/619248
    Type
    Other
    Language
    en
    Description
    Research Protocol
    Collections
    MSF Research Protocols

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.